Efficacy and Safety of a Regimen for Medical Abortion up to 63 Days of Gestation: A Retrospective Study in Northern Greece

被引:0
|
作者
Kelesidou, Vera [1 ]
Tsakiridis, Ioannis [1 ]
Mitta, Kyriaki [1 ]
Virgiliou, Andriana [1 ]
Michos, Georgios [1 ]
Kougioumtsidou, Anna [1 ]
Mamopoulos, Apostolos [1 ]
Dagklis, Themistoklis [1 ]
Kalogiannidis, Ioannis [1 ]
机构
[1] Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Dept Obstet & Gynaecol 3, Thessaloniki 54124, Greece
关键词
medical abortion; misoprostol; mifepristone; early pregnancy; first trimester; VAGINAL MISOPROSTOL; MIFEPRISTONE RU-486; PREGNANCY; PROSTAGLANDIN; TERMINATION;
D O I
10.3390/jcm14041235
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: First trimester medical abortion with the combination of mifepristone and misoprostol is highly effective. The aim of this study was to assess the efficacy and safety of a modified medical abortion protocol, offering a structured outpatient approach up to 9 weeks (63 days) of gestation. This study may contribute to existing evidence by evaluating a slightly altered regimen and its real-world effectiveness in clinical practice. Material and Methods: This was a retrospective cohort study conducted at the Third Department of Obstetrics and Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece, during a two-year period (2022-2024). Women aged 18 years or older with an intrauterine pregnancy <= 63 days confirmed by transvaginal ultrasound were included. Exclusion criteria included ectopic pregnancy, contraindications to study medications, or loss to follow-up. Mifepristone (200 mg) was administered orally on Day 1, and misoprostol (800 mcg) was administered vaginally on Day 3. Serial follow-up visits on Days 8, 15, and 21 were scheduled according to the success of each cycle. Results: In total, 130 women were included in the study. A high success rate of 96.9% (95% CI: 92.3-99.2%) was observed. Success was most frequently observed on Day 8 (60.8%). Success rates were 100% for the age group of 18 to 25 years, approximately 96% for both the groups of 26-35 and 36-45 years, and around 50% for those aged >45 years. With regards to gestational age, success rates were 97.5% for <= 7 weeks (49 days) and 95.9% for >7 weeks (p = 0.63). Side effects were reported by 13.2% of participants (95% CI: 7.8-20.1%) and mainly involved the gastrointestinal system. Pain intensity was reported as moderate; analgesics were used by 75.4% of patients. The satisfaction rate for the medical abortion process was 95.4% (95% CI: 90.2-98.3%). Conclusions: Early-first-trimester medical abortion on an outpatient basis is a feasible, patient-friendly method with high efficacy, exhibiting limited side effects and a high satisfaction rate.
引用
收藏
页数:8
相关论文
共 35 条
  • [21] Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation
    Bartley, J
    Brown, A
    Elton, R
    Baird, DT
    HUMAN REPRODUCTION, 2001, 16 (10) : 2098 - 2102
  • [22] A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation
    Dzuba, Ilana G.
    Chong, Erica
    Hannum, Curtiss
    Lichtenberg, E. Steve
    Lugo Hernandez, Elba Margarita
    Nguyen Thi Nhu Ngoc
    Patel, Ashlesha
    Rzayeva, Gulnara
    Sanhueza Smith, Patricio
    Tsertsvadze, George
    Winikoff, Beverly
    CONTRACEPTION, 2020, 101 (05) : 302 - 308
  • [23] Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability
    Ngai, SW
    Tang, OS
    Chan, YM
    Ho, PC
    HUMAN REPRODUCTION, 2000, 15 (05) : 1159 - 1162
  • [24] Does prior ultrasonographyaffect the safety of induced abortion at or after 13 weeks' gestation? A retrospective study
    Kapp, Nathalie
    Griffin, Risa
    Bhattaraij, Navaraj
    Dangol, Deeb Shrestha
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2021, 100 (04) : 736 - 742
  • [25] Multi-level pregnancy test use for medical abortion follow-up after 63 days' gestation: Evidence from prenatal hCG data
    Shochet, Tara
    Lerma, Klaira
    Blum, Jennifer
    Winikoff, Beverly
    Blumenthal, Paul D.
    CONTRACEPTION, 2020, 102 (03) : 207 - 209
  • [26] A repeat dose of misoprostol 800 mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review
    Dzuba, Ilana G.
    Castillo, Philicia W.
    Bousieguez, Manuel
    Lugo Hernandez, Elba Margarita
    Castaneda Vivar, Jose Juan
    Sanhueza Smith, Patricio
    CONTRACEPTION, 2020, 102 (02) : 104 - 108
  • [27] Comparative study of medical abortion by Mifepristone with vaginal Misoprostol in women < 49 days versus 50 - 63 days of amenorrhoea
    Sonali, Deshpande
    Kanan, Yelikar
    Ajit, Deshmukh
    Kapil, Kanade
    JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA, 2010, 60 (05) : 403 - 407
  • [28] Comparative study of medical abortion by Mifepristone with vaginal Misoprostol in women < 49 days versus 50-63 days of amenorrhoea""
    Sonali D.
    Kanan Y.
    Ajit D.
    Kapil K.
    The Journal of Obstetrics and Gynecology of India, 2010, 60 (5) : 403 - 407
  • [29] Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: A quasi-randomized controlled trial
    Chawdhary, Rashmi
    Rana, Ashma
    Pradhan, Neelam
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2009, 35 (01) : 78 - 85
  • [30] Short-term efficacy and safety of early medical abortion in Japan: A multicenter prospective study
    Osuga, Yutaka
    Shirasu, Kazuhiro
    Tsushima, Ruriko
    Ishitani, Ken
    REPRODUCTIVE MEDICINE AND BIOLOGY, 2023, 22 (01)